The Schizophrenic Valuation of Bristol Myers Squibb: A 4.6% Safety Net Over a Patent Abyss

Thank you to everyone who tuned into my live video! Join me for my next live video in the app.

1. The Hook: A $111 Billion Identity Crisis

In the high-stakes theater of biotech investing, there is no siren song more seductive—or more dangerous—than a blue-chip giant trading at a structural discount. Bristol Myers Squibb ($BMY) currently finds itself in the throes of a $111 billion identity crisis. Trading at a price of $54.80, the company is attempting a “quantamental” metamorphosis: shedding its skin as a legacy pharmaceutical titan to emerge as a nimble, high-science innovator. For the sophisticated observer, the central question is whether this is a generational “deep value” entry point or a structural value trap where the “new” BMY—symbolized by its high-potential schizophrenia therapy, Cobenfy—cannot grow fast enough to outrun the decay of its past.